Deepverge PLC Update - Proposed Financing,Proposed Board Changes (9515D)

TIDMDVRG

RNS Number : 9515D

Deepverge PLC

25 October 2022

DeepVerge PLC

("DeepVerge" or "Company")

Update on Proposed Financing / Proposed Board Changes

DeepVerge (AIM: DVRG), the environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins, announces an update on the Proposed Financing and details of proposed changes to the board, and to the roles undertaken by existing directors.

Update on Proposed Financing

Further to the RNS announcement of 12 October 2022, the Board is pleased to advise that the fundraising process, coordinated by the Company's brokers Turner Pope, continues to progress, despite challenging market conditions. We look forward to updating shareholders and the market in the near term. H owever, there can be no guarantee that sufficient equity funds can be raised, nor the terms thereof.

Board and Management changes

The Company has doubled turnover every year from GBP0.27m in 2018 to GBP9.3m in 2021 with a forecast of GBP18m this year.

This fast pace of growth has stretched both the balance sheet and the existing management team. As a consequence a new CEO, CFO and Non-Executive director will be recruited.

The following Board changes are expected to take effect immediately upon the announcement of the Proposed Financing:

Gerard Brandon will step down as Chief Executive remaining on the board as Executive Director with responsibility for the Modern Water Division.

Dr Nigel Burton will become interim Chief Executive while the Company commences the search for a new Group Chief Executive.

Fionan Murray will remain on the Board as Executive Director with responsibility for the Skin Trust Club and Labskin Division.

Camillus Glover will leave the board but will remain as Chief Financial Officer while the Company commences the search for a new Group Finance Director.

A further independent non-executive director will be appointed as soon as practicable.

For further information, please contact:

Enquiries:

 
 DeepVerge plc              Ross Andrews, Chairman    +44 (0) 1904 40 4036 
 
 SPARK Advisory Partners 
  Limited 
  (Nominated Adviser)       Neil Baldwin              +44 (0) 113 370 8974 
 
 Turner Pope Investments 
  (TPI) Limited             Andy Thacker/James 
  (Broker)                   Pope                     +44 (0) 20 3657 0050

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFELEDLEESESS

(END) Dow Jones Newswires

October 25, 2022 02:01 ET (06:01 GMT)

Integumen (LSE:SKIN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024